IP Library Granted Patent US 9,000,039
Granted Patent B2
US 9,000,039 · App. 14/009,981 · Granted Apr 7, 2015

Sn-1(3) monoacylglycerides and lipid absorption

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,000,039
App. No.
14/009,981
Granted
Apr 7, 2015
Kind
B2
Abstract

The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising sn-1(3) monoacylglycerols, wherein the sn-1 or sn-3 position is occupied by an acyl group such as a fatty acid and the sn-2 position remains unoccupied. The fatty acid may be one with anti-inflammatory properties.

Claims (15)

1. A method for the treatment of inflammatory disorders, the method comprising administering to a subject suffering from a lipid maldigestion or malabsorption condition a composition comprising a sn-1(3)-monoacylglycerol, wherein the acyl group is a fatty acid having anti-inflammatory properties, the fatty acid selected from the group consisting of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), α-linolenic acid (ALA), stearidonic acid, γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), n-3 docosapentanenoic acid (DPA), sciadonic acid, juniperonic acid, and combinations thereof.

2. The method of claim 1 , wherein the sn-1(3)-monoacylglycerol is selected from the group consisting of sn-1(3)-monoeicosapentaenoylglycerol, sn-1(3)-mono docosahexaenoylglycerol, sn-1(3)-monooctadecatrienoylglycerol, sn-1(3)-monooctadecatetraenoylglycerol, sn-1(3)-monoeicosatrienoylglycerol, sn-1(3)-mono docosapentaenoylglycerol, sn-1(3)-monosciadonylglycerol, sn-1(3)-monojuniperonylglycerol or combinations thereof.

3. The method claim 1 , wherein the sn-1(3)-monoacylglycerol is sn-1(3)monoeicosapentaenoylglycerol.

4. The method of claim 1 , wherein no more than 25 weight-% of the total monoacylglycerols are sn-2 monoacylglycerols.

5. The method of claim 1 , wherein the composition has a pH of 5-8.

6. The method of claim 1 , wherein the composition is to be stored at 8° C. or below.

7. The method of claim 1 , wherein the composition comprises a lipase B inhibitor.

8. The method of claim 1 , wherein the composition is selected from the group consisting of a food product, an animal food product, a pharmaceutical composition, a nutritional composition, a nutraceutical, a drink, a food additive and a medicament.

9. The method of claim 1 , wherein the composition has a caloric density of 0.5 kcal/ml to 15 kcal/ml.

10. The method of claim 1 , wherein the sn-1(3)-monoacylglycerol derivative provides about 5% to 40% of the energy of the composition.

11. The method of claim 1 , wherein the sn-1(3)-monoacylglycerol derivative provides about 5% to 40% of the energy of the composition.

12. The method of claim 1 , wherein the composition contains a combination of different sn-1(3)-monoacylglycerol derivatives.

13. The method of claim 1 for use in the delivery of fatty acids having anti-inflammatory properties.

14. The method of claim 1 , wherein the malabsorption condition is due to pancreatic insufficiency, bile salt deficiency, a mucosal disorder and/or a short gut.

15. The method of claim 1 , wherein the inflammatory disorder is selected from the group consisting of acute inflammations, chronic inflammations, Crohn's disease, ulcerative colitis, necrotizing enterocolitis, skin inflammation, inflammatory bowel syndrome, liver inflammation, alcoholic cirrhosis, allergy, atopy, bone inflammation, rheumatoid arthritis, systemic lupus, dermato-myositis, thyroiditis, type I diabetes, celiac disease, Biermer's disease, multiple sclerosis, encephalomyelitis, eye inflammation, obesity-associated inflammation, age-related low-grade inflammation, Blau's syndrome, Alzheimer's disease, cardiovascular diseases, atherosclerosis, and metabolic syndrome.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2014
From: DESTAILLATS, FREDERIC; CRUZ-HERNANDEZ, CRISTINA; DIONISI, FABIOLA; MASSEREY-ELMELEGY, ISABELLE; OLIVEIRA, MANUEL; MOULIN, JULIE CELINE
To: NESTEC S.A.
Reel/Frame 032333/0371 →